| First Author | Kim YY | Year | 2022 |
| Journal | Diabetes | Volume | 71 |
| Issue | 7 | Pages | 1373-1387 |
| PubMed ID | 35476750 | Mgi Jnum | J:326873 |
| Mgi Id | MGI:7314383 | Doi | 10.2337/db21-0649 |
| Citation | Kim YY, et al. (2022) Hepatic GSK3beta-Dependent CRY1 Degradation Contributes to Diabetic Hyperglycemia. Diabetes 71(7):1373-1387 |
| abstractText | Excessive hepatic glucose production (HGP) is a key factor promoting hyperglycemia in diabetes. Hepatic cryptochrome 1 (CRY1) plays an important role in maintaining glucose homeostasis by suppressing forkhead box O1 (FOXO1)-mediated HGP. Although downregulation of hepatic CRY1 appears to be associated with increased HGP, the mechanism(s) by which hepatic CRY1 dysregulation confers hyperglycemia in subjects with diabetes is largely unknown. In this study, we demonstrate that a reduction in hepatic CRY1 protein is stimulated by elevated E3 ligase F-box and leucine-rich repeat protein 3 (FBXL3)-dependent proteasomal degradation in diabetic mice. In addition, we found that GSK3beta-induced CRY1 phosphorylation potentiates FBXL3-dependent CRY1 degradation in the liver. Accordingly, in diabetic mice, GSK3beta inhibitors effectively decreased HGP by facilitating the effect of CRY1-mediated FOXO1 degradation on glucose metabolism. Collectively, these data suggest that tight regulation of hepatic CRY1 protein stability is crucial for maintaining systemic glucose homeostasis. |
